Edible cannabis caused more psychiatric and cardiovascular ER visits than expected based on sales volume

Edible cannabis ER visits were disproportionate to sales (10.7% of visits vs 0.32% of THC sales). Compared to inhaled, edible visits had more psychiatric symptoms (18% vs 10.9%), intoxication (48% vs 28%), and cardiovascular symptoms (8% vs 3.1%). Inhaled cannabis visits more often involved cannabinoid hyperemesis (18% vs 8.4%).

Chart review of 9,973 ER visits with cannabis ICD codes at a large urban Colorado hospital (2012-2016). 2,567 (25.7%) were at least partially attributable to cannabis. Compared clinical presentations by route of exposure.

This is the definitive study showing edibles are disproportionately represented in ER visits. The disconnect between sales volume and ER visits suggests that edibles pose unique risks, likely related to delayed onset and difficulty dosing.

Annals of Internal Medicine publication gives this finding high credibility. The data suggests cannabis policy should differentiate between consumption methods, with edibles requiring specific dosing guidance, labeling, and public education.

Single academic center in Colorado. Self-reported exposure data. Limited dose information available. Cannot determine whether edible users consumed more THC or were simply more sensitive to its effects.